| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911647 | Lung Cancer | 2005 | 8 Pages |
Abstract
In conclusion, cisplatin plus epirubicin appears as an effective regimen in malignant mesothelioma, with a favourable toxicity profile. However, it does not demonstrate superior activity to other active regimens in this disease.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
T. Berghmans, J.J. Lafitte, M. Paesmans, B. Stach, M.C. Berchier, P. Wackenier, J. Lecomte, T. Collon, P. Mommen, J.P. Sculier, For the European Lung Cancer Working Party (ELCWP) For the European Lung Cancer Working Party (ELCWP),